ACTIVE SESSION TAPE Biotechnology $11M Cap Quant: HOLD

Why Is Lyra Therapeutics, Inc. (LYRA) Stock Down Today?

Updated Nov 17, 2026 2:49 PM ET · Prev Close $1.32

Pro Workspace
Last Session Price
$0.49 -62.50%
-$0.83 vs $1.32 prior close
Intraday Range
$0.48 – $1.33
Open $1.29
Relative Volume
1.00x Avg
1,174,866 sh
52-Week Range
$0.48 – $1.33
Benchmark Alpha
-61.16% vs SPY
-61.23% vs QQQ
20-Session Trend
Click Interactive Chart for full OHLCV history

Session Regime & Catalyst Assessment

68% Signal Conviction
TECHNICAL 68% Driver Weight

Lyra Therapeutics, Inc. Pulling Back 62.50% on 1.00x Relative Volume

Lyra Therapeutics, Inc. (LYRA) is pulling back 62.50% (-$0.83) to $0.49 on 1.00x average session volume. Relative to benchmarks, LYRA is lagging the S&P 500 by -61.16%. 14-day RSI stands at 21.5, keeping momentum in a oversold regime.

NEWS 70% Weight
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

Watertown, Mass., April 17, 2026 Globe Newswire -- Lyra Therapeutics, Inc. the Company today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commissio

TECHNICAL 68% Weight
Moving Average Structure: Bearish Alignment

Price ($0.49) trades relative to 20-day SMA ($1.27) and 50-day SMA ($1.82).

Volume Confirmation
MODERATE VOLUME (1.00x) Normal
Institutional participation confirms directional price action.
Composite Catalyst Confidence 68%
Cross-checked across volume tape, benchmark alpha, options flow, and news.

Market & Sector Relative Strength

LYRA lagging the S&P 500 by -61.16%
LYRA Session
-62.50%
$0.49
S&P 500 (SPY)
-1.34%
$730.04
Nasdaq 100 (QQQ)
-1.27%
$653.34
Healthcare (XLV)
-1.36%
$185.33
Alpha vs SPY: -61.16% Alpha vs QQQ: -61.23% Alpha vs XLV: -61.14%

Options Flow & Execution Desk

Recent LYRA Catalyst Headlines

Verified Wire
Lyra Therapeutics suspends further development of Lyr-210

Lyra Therapeutics LYRA , announced that its Board of Directors has decided to suspend further development of Lyr-210, the Company s lead product candidate for the treatment of chronic rhinosinusitis. The Company also ann

Yahoo Finance · Jan 13, 2026
Lyra Therapeutics Provides Corporate Update

Watertown, Mass., Jan. 12, 2026 Globe Newswire -- Lyra Therapeutics, Inc. Nasdaq LYRA Lyra or the Company today announced that its Board of Directors has decided to suspend further development of Lyr-210, the Company s l

Yahoo Finance · Jan 12, 2026

1–3 Day Expected Range & Key Level

54% Follow-Through
Lower Bound
$0.46
Short-term support band
Upper Bound
$0.52
Short-term resistance band
Key Inflection Level
$0.48 (session support)

Monitor volume expansion above 1.5x RVOL around $0.48 (session support) for directional breakout confirmation.

Technical Regime (LYRA)

BEARISH MA TREND
RSI (14)
21.5
Oversold
20-Day SMA
$1.27
Below 20d
50-Day SMA
$1.82
Below 50d
MACD Signal
Bullish
MACD -0.22
ADX (14)
31.0
Strong trend
10d Momentum
-0.69
Soft 10-day momentum

Retail & Crowd Sentiment

Neutral
24h Messages
0
7d avg 0.0
Bullish / Bearish
0.0% / 0.0%
None buzz
Crowd Discussion Digest

Negative sentiment prevails on $LYRA as delisting and appeal rejection messages circulate on StockTwits, with no positive news articles to offset the bearish tone.

Reddit communities: 1 comment (Neutral)

About Lyra Therapeutics, Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT …

Sector
Healthcare
Market Cap
$11M
Employees
30

Get Instant LYRA Catalyst Alerts

Receive an email alert when LYRA triggers an unusual volume breakout, options sweep, or rating shift.

Other Liquid Stocks Moving Today

All Today's Movers

LYRA Session & Catalyst FAQ

Why is LYRA stock down today?

Lyra Therapeutics, Inc. (LYRA) is pulling back 62.50% (-$0.83) to $0.49 on 1.00x average session volume. Relative to benchmarks, LYRA is lagging the S&P 500 by -61.16%. 14-day RSI stands at 21.5, keeping momentum in a oversold regime.

Is LYRA stock a buy or sell right now?

Today's session carries a 68% catalyst conviction score on 1.00x relative volume (moderate participation). Our multi-factor model currently rates LYRA as HOLD. Review full valuation, quality, and timing signals on the LYRA Buy or Sell Decision Brief →

What is LYRA's intrinsic value and expected trading range?

At $0.49, LYRA's modeled 1-to-3 session range is $0.46 – $0.52, with a key inflection level at $0.48 (session support). Compare current price against multi-year cash flow projections in the LYRA Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →

What do RSI and moving averages signal for LYRA?

RSI at 21.5 indicates oversold conditions — watch for mean-reversion support. LYRA trades at $0.49 relative to its 20-day SMA ($1.27) and 50-day SMA ($1.82), reflecting a bearish moving-average structure.

Tradestie Flagship Research & Market Hubs